LeMaitre Vascular (NASDAQ:LMAT) Stock Rating Upgraded by StockNews.com

LeMaitre Vascular (NASDAQ:LMAT) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday.

A number of other analysts also recently commented on the stock. KeyCorp assumed coverage on shares of LeMaitre Vascular in a research report on Tuesday, February 6th. They set a “sector weight” rating on the stock. JMP Securities upped their target price on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a research report on Friday. Stifel Nicolaus raised LeMaitre Vascular from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. Finally, Barrington Research raised their target price on LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a research note on Friday. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and a consensus price target of $73.83.

LeMaitre Vascular Price Performance

LMAT opened at $74.22 on Friday. The stock’s 50 day moving average price is $65.93 and its 200 day moving average price is $58.78. The stock has a market cap of $1.67 billion, a P/E ratio of 49.15, a P/E/G ratio of 3.20 and a beta of 0.88. LeMaitre Vascular has a 12 month low of $44.27 and a 12 month high of $74.64.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a return on equity of 11.75% and a net margin of 16.99%. The company had revenue of $53.48 million for the quarter, compared to analyst estimates of $51.50 million. During the same period last year, the company earned $0.27 earnings per share. The company’s quarterly revenue was up 13.6% compared to the same quarter last year. Equities analysts anticipate that LeMaitre Vascular will post 1.77 EPS for the current year.

Insider Buying and Selling

In other news, Director Lawrence J. Jasinski sold 5,110 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the sale, the director now directly owns 5,309 shares of the company’s stock, valued at $358,357.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other LeMaitre Vascular news, Director Lawrence J. Jasinski sold 5,110 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total value of $344,925.00. Following the completion of the transaction, the director now directly owns 5,309 shares in the company, valued at $358,357.50. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Joseph P. Pellegrino, Jr. sold 36,967 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $69.76, for a total transaction of $2,578,817.92. Following the sale, the chief financial officer now owns 6,452 shares in the company, valued at approximately $450,091.52. The disclosure for this sale can be found here. Insiders have sold 114,036 shares of company stock worth $7,873,749 in the last three months. 10.79% of the stock is currently owned by insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Several hedge funds have recently bought and sold shares of the business. Mesirow Institutional Investment Management Inc. purchased a new position in LeMaitre Vascular during the 4th quarter valued at about $8,837,000. Congress Asset Management Co. MA grew its position in LeMaitre Vascular by 36.3% during the third quarter. Congress Asset Management Co. MA now owns 508,379 shares of the medical instruments supplier’s stock valued at $27,696,000 after purchasing an additional 135,266 shares in the last quarter. Ranger Investment Management L.P. lifted its position in LeMaitre Vascular by 15.8% in the 3rd quarter. Ranger Investment Management L.P. now owns 898,822 shares of the medical instruments supplier’s stock worth $48,968,000 after buying an additional 122,601 shares in the last quarter. Summit Creek Advisors LLC boosted its stake in shares of LeMaitre Vascular by 37.8% during the 4th quarter. Summit Creek Advisors LLC now owns 228,501 shares of the medical instruments supplier’s stock valued at $12,970,000 after buying an additional 62,737 shares during the period. Finally, Conestoga Capital Advisors LLC grew its holdings in shares of LeMaitre Vascular by 3.0% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,917,581 shares of the medical instruments supplier’s stock valued at $104,470,000 after acquiring an additional 55,895 shares in the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.